Skip to main content
PRLD logo

PRLD · Prelude Therapeutics Inc · Webcasts, Transcripts & Audio

Track PRLD — free
$3.23 -0.03 (-0.77%) At close · Nov 20 Play latest call Q3 2025 earnings call transcript
Market Cap
$258.63M
Shares
80.07M
Volume · Nov 20 300.1K Avg daily vol (3M) 434.45K

Prelude Therapeutics Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Prelude Therapeutics Inc (PRLD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-12-02
Prelude Therapeutics Inc (PRLD) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-16
Prelude Therapeutics Inc (PRLD) Q3 2026 Earnings Call
Revenue
$5.65M
▼ 13.1% YoY
Diluted EPS
$-0.12
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-10-20
Prelude Therapeutics Inc (PRLD) October 20, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-16
Prelude Therapeutics Inc (PRLD) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-10
Prelude Therapeutics Inc (PRLD) June 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Prelude Therapeutics Inc (PRLD) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-03-10
Prelude Therapeutics Inc (PRLD) Q4 2025 Earnings Call
Revenue
$5.64M*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Prelude Therapeutics Inc (PRLD) Q3 2025 Earnings Call Transcript
Positive tone CAP-6A selective degrader program Insight option agreement / business development JAK2V617F selective inhibitor program
Revenue
$6.50M
▲ 116.7% YoY
Diluted EPS
$-0.26
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Prelude Therapeutics Inc (PRLD) Q1 2025 Earnings Call
Revenue
$0
Diluted EPS
$-0.42
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-10
Prelude Therapeutics Inc (PRLD) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Prelude Therapeutics Inc (PRLD) Q3 2024 Earnings Call
Revenue
$3.00M
Diluted EPS
$-0.43
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 webcasts
Key facts CIK 1678660 CUSIP 74065P101 13F (30d) 104 filings 90 filers Visit website Investor relations